Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Glazer
Yale University, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Patrys Limited
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Please see the uploaded attachment for the required information.
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy. We have discovered that a cell-penetrating, anti-DNA antibody (3E10) can increase the sensitivity of cancer cells to radiation and chemotherapy but is otherwise non-toxic to human cells. We will investigate the mechanism of action of 3E10, elucidate how it can best be combined with radiation and chemotherapy, identify potential synthetic lethal interactions in DNA repair-deficient cancer cells, and establish its effectiveness in vivo in mouse tumor models of human cancers. We expect that this work will provide key data to support the utility of 3E10 in cancer therapy and to define initial effective means of use.
Filed on June 15, 2016.
Tell us what you know about Peter Glazer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Peter Glazer filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Glazer | Yale University | Conflict of Interest | Patrys, Limited | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Cybrexa Therapeutics | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | TruCode | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | TruCode Gene Repair, Inc. | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Tru Code (formerly PNA Innovations) | $20,000 - $39,999 |
| Peter Glazer | Yale University | Conflict of Interest | Tru Code (formerly PNA Innovations) | Value cannot be readily determined |
| Peter Glazer | Yale University | Conflict of Interest | Cybrexa Therapeutics | Value cannot be readily determined |
| Peter Glazer | Yale University | Conflict of Interest | TruCode Gene Repair, Inc. | Value cannot be readily determined |
| Peter Glazer | Yale University | Conflict of Interest | TruCode | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.